Their findings suggest that targeting the EGFR–PI3K–AKT–GSK3β–SREBP1 axis or inhibiting SREBP1 directly could serve as potential therapeutic strategies for breast cancer, especially in obesity-associated cases where visfatin levels are elevated. The gene discussed is SREBF1; the disease is obesity due to melanocortin 4 receptor deficiency.